Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
A monoclonal thyroid-stimulating antibody
Takao Ando, … , Yuji Nagayama, Terry F. Davies
Takao Ando, … , Yuji Nagayama, Terry F. Davies
Published December 1, 2002
Citation Information: J Clin Invest. 2002;110(11):1667-1674. https://doi.org/10.1172/JCI16991.
View: Text | PDF
Article Autoimmunity

A monoclonal thyroid-stimulating antibody

  • Text
  • PDF
Abstract

Research Article

Authors

Takao Ando, Rauf Latif, Alla Pritsker, Thomas Moran, Yuji Nagayama, Terry F. Davies

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
Dose-response study of the blocking activity of MS-1. CHO-hTSHR cells we...
Dose-response study of the blocking activity of MS-1. CHO-hTSHR cells were stimulated with MS-1 at the indicated concentrations with or without 100 μU/ml of TSH. Since MS-1 is a TSHR-stimulating monoclonal antibody, the cAMP generated by MS-1 alone was subtracted from the cAMP generated by MS-1 plus TSH. Medium alone produced less than 50 fmol/well cAMP, and TSH (100 μU/ml) generated 2,000 fmol/well.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts